Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225 - PubMed (original) (raw)
. 1999 Jan 21;18(3):731-8.
doi: 10.1038/sj.onc.1202319.
Affiliations
- PMID: 9989823
- DOI: 10.1038/sj.onc.1202319
Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225
D Ye et al. Oncogene. 1999.
Abstract
Overexpression of epidermal growth factor (EGF) receptor and HER2 (p185neu) may both contribute to the growth of human cancers. A humanized anti-HER2 monoclonal antibody (mAb) 4D5 and a human-mouse chimeric anti-EGF receptor mAb C225 are currently being investigated in clinical trials for their anti-tumor activities. In the present study, we have examined the effect of concurrent treatment of OVCA 420 human ovarian cancer cells with mAb C225 and mAb 4D5. Exposure of OVCA420 cells to saturating concentrations of C225 (20 nM) for 7 days resulted in 40-50% growth inhibition, and exposure to 20 nM mAb 4D5 also resulted in 30-40% growth inhibition. The growth inhibition of OVCA420 cells by mAb C225 or 4D5 was associated with an increased G1 cell population; an increased level of a cyclin-dependent kinase (CDK) inhibitor p27Kip1 with increased association of p27kip1 with CDK2, CDK4 and CDK6; and decreased activities of these CDKs. Combination treatment with concurrent exposure to mAbs C225 and 4D5 resulted in additive anti-proliferative effects on these cells, which was accompanied by enhanced G1 cell distribution, a greater increase in the levels of p27Kip1 and a greater decrease in the activities of CDK kinases. The anti-proliferative effects and related changes in cell cycle regulators induced by mAb 4D5, mAb C225 or the combination of the two mAbs could be reversed by concurrent exposure to exogenous EGF. Our data suggest the potential fruitful cooperation of anti-EGF receptor mAb and anti-HER2 mAb in the treatment of human cancers stimulated by EGF receptor and HER2 signals.
Similar articles
- Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody.
Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn J. Wu X, et al. Oncogene. 1996 Apr 4;12(7):1397-403. Oncogene. 1996. PMID: 8622855 - Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.
Lane HA, Motoyama AB, Beuvink I, Hynes NE. Lane HA, et al. Ann Oncol. 2001;12 Suppl 1:S21-2. doi: 10.1093/annonc/12.suppl_1.s21. Ann Oncol. 2001. PMID: 11521716 Review. - The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.
Mendelsohn J. Mendelsohn J. Semin Cancer Biol. 1990 Oct;1(5):339-44. Semin Cancer Biol. 1990. PMID: 2103507 Review.
Cited by
- Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements.
Akter S, Rahman MA, Hasan MN, Akhter H, Noor P, Islam R, Shin Y, Rahman MDH, Gazi MS, Huda MN, Nam NM, Chung J, Han S, Kim B, Kang I, Ha J, Choe W, Choi TG, Kim SS. Akter S, et al. Cells. 2022 Feb 13;11(4):650. doi: 10.3390/cells11040650. Cells. 2022. PMID: 35203301 Free PMC article. Review. - Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells.
Masuelli L, Fantini M, Benvenuto M, Sacchetti P, Giganti MG, Tresoldi I, Lido P, Lista F, Cavallo F, Nanni P, Schlom J, Modesti A, Bei R. Masuelli L, et al. J Transl Med. 2014 May 10;12:122. doi: 10.1186/1479-5876-12-122. J Transl Med. 2014. PMID: 24886178 Free PMC article. - Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL. Wang M, et al. J Cancer Res Clin Oncol. 2012 Dec;138(12):2069-77. doi: 10.1007/s00432-012-1291-2. Epub 2012 Jul 22. J Cancer Res Clin Oncol. 2012. PMID: 22821179 - Identifying microRNA/mRNA dysregulations in ovarian cancer.
Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Miles GD, et al. BMC Res Notes. 2012 Mar 27;5:164. doi: 10.1186/1756-0500-5-164. BMC Res Notes. 2012. PMID: 22452920 Free PMC article. - EGFR/HER-targeted therapeutics in ovarian cancer.
Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ. Wilken JA, et al. Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11. Future Med Chem. 2012. PMID: 22416774 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous